Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

BACKGROUND: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval. METHODS: Pts with previously treated advanced or mRCC were eligible to receive...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Main Authors: Verzoni, Elena, Cartenì, Giacomo, Cortesi, Enrico, Giannarelli, Diana, De Giglio, Andrea, Sabbatini, Roberto, Buti, Sebastiano, Rossetti, Sabrina, Cognetti, Francesco, Rastelli, Francesca, Sobrero, Alberto, Turci, Daniele, Sternberg, Cora N., Porta, Camillo, Cappuzzo, Federico, Tortora, Giampaolo, Tassinari, Davide, Panni, Stefano, Pazzola, Antonio, Surico, Gianmarco, Raimondi, Alessandra, De Giorgi, Ugo, Procopio, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2019
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6448290/
https://ncbi.nlm.nih.gov/pubmed/30944023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0579-z
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares